Search results
Showing 1171 to 1185 of 1300 results for heart OR cardi* OR arrythmia
Empagliflozin for reducing the risk of cardiovascular events in type 2 diabetes [ID1037]
Discontinued Reference number: GID-TA10177
Adalimumab and dexamethasone for treating non-infectious uveitis (TA460)
Evidence-based recommendations on adalimumab (Humira) and dexamethasone (Ozurdex) for treating non-infectious uveitis in adults.
This guideline covers care before, during and after a planned knee, hip or shoulder replacement. It includes recommendations to ensure that people are given full information about their options for surgery, including anaesthesia. It offers advice for healthcare professionals on surgical procedures and ensuring safety during operations. It also offers guidance on providing support and rehabilitation before and after surgery.
This guideline has been updated and replaced by NICE guideline NG185.
This guidance has been updated and replaced by NICE guideline CG181.
Cardiovascular disease: risk assessment and reduction, including lipid modification (CG181)
This guideline has been updated and replaced by NICE guideline NG238.
Evidence-based recommendations on baricitinib (Olumiant) for treating severe alopecia areata in adults.
Implantable cardioverter defibrillators for arrhythmias (TA95)
This guidance has been updated and replaced by NICE technology appraisal guidance 314.
Implantable cardioverter defibrillators (ICDs) for the treatment of arrhythmias (TA11)
This guidance has been replaced by NICE technology appraisal guidance 95 [Replaced by NICE technology appraisal guidance 314].
Tafamidis for treating transthyretin amyloidosis with cardiomyopathy (TA696)
This guidance has been updated and replaced by NICE technology appraisal guidance 984.
Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia (TA193)
Evidence-based recommendations on rituximab for treating relapsed or refractory chronic lymphocytic leukaemia in adults.
Rituximab for the first-line treatment of chronic lymphocytic leukaemia (TA174)
Evidence-based recommendations on rituximab for untreated chronic lymphocytic leukaemia in adults.
Evidence-based recommendations on vadadustat (Vafseo) for treating symptomatic anaemia in adults having dialysis for chronic kidney disease.
Enzalutamide for hormone-relapsed non-metastatic prostate cancer (TA580)
Evidence-based recommendations on enzalutamide (Xtandi) for treating high-risk hormone-relapsed non-metastatic prostate cancer in adults.
Evidence-based recommendations on continuous positive airway pressure for treating obstructive sleep apnoea/hypopnoea syndrome in adults.